Neoadjuvant Endocrine Treatment for Breast Cancer
نویسندگان
چکیده
25/18_suppl/538; cited December 9, 2013] 35. Ali AM, Provenzano E, Bartlett JM. et al. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the neat/br9601 trial. Int J Cancer 2013;133:1470–8. 36. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor–positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380–8. 37. Ellis M, Suman V, Hoog J, et al. acosog Z1031: a randomized neoadjuvant comparison between letrozole (let), anastrozole (ana) and exemestane (exe) for postmenopausal women with er rich stage 2/3 breast cancer: biomarker outcomes and the predictive value of the baseline pam50 based intrinsic subtype [abstract S1-2]. Cancer Res 2010;70(suppl 2):. [Available online at: http://cancerres.aacrjournals.org/cgi/content/ meeting_abstract/70/24_MeetingAbstracts/S1-2; cited De-
منابع مشابه
Neoadjuvant Endocrine Therapy for Breast Cancer: Medical Perspectives 1
The indolent nature of estrogen-dependent breast cancer is the most important obstacle for development of new adjuvant endocrine treatments. Clinical trials require thousands of study participants and at least a decade of clinical investigation. How can we be sure that a new endocrine agent warrants this extraordinary level of investment? Traditionally, we have relied on advanced breast cancer ...
متن کاملNeoadjuvant Endocrine Therapy for Breast Cancer: Medical Perspectives 1
The indolent nature of estrogen-dependent breast cancer is the most important obstacle for development of new adjuvant endocrine treatments. Clinical trials require thousands of study participants and at least a decade of clinical investigation. How can we be sure that a new endocrine agent warrants this extraordinary level of investment? Traditionally, we have relied on advanced breast cancer ...
متن کاملRecent Advances in the Neoadjuvant Treatment of Breast Cancer
In the last few decades, neoadjuvant therapy for breast cancer has gained considerable therapeutic importance. Despite extensive clinical investigations, it has not yet been clarified whether neoadjuvant therapy would result in improved survival in comparison with the standard adjuvant setting in any subgroups of patients with breast cancer. Chemotherapy is especially effective in the treatment...
متن کاملAssociation of tumor infiltration lymphocytes and complete pathological response in breast cancer patients under neoadjuvant chemotherapy
Background: The breast cancer is the most common type of cancer in Iran. Hence determination of the optimal treatment and the contributing factors are important. The main aim in current study was to determine the association between tumor infiltration of lymphocytes (TIL) and complete pathological response in breast cancer patients after neoadjuvant chemotherapy. Methods and materials: In this...
متن کاملPrognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
Background and objective:Breast cancer is the most common malignancy among women. The Neoadjuvant chemotherapy is the treatment of choice for non-operable tumors. The Ki67 is a proliferation marker that can be used to predict the therapeutic response to chemotherapy and the patients' prognosis. Methods: This retrospective study was carri...
متن کاملNeoadjuvant endocrine therapy for breast cancer: medical perspectives.
The indolent nature of estrogen-dependent breast cancer is the most important obstacle for development of new adjuvant endocrine treatments. Clinical trials require thousands of study participants and at least a decade of clinical investigation. How can we be sure that a new endocrine agent warrants this extraordinary level of investment? Traditionally, we have relied on advanced breast cancer ...
متن کامل